Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001845041-25-000005
Filing Date
2025-11-12
Accepted
2025-11-12 16:30:21
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 38901
  Complete submission text file 0001845041-25-000005.txt   40534
Mailing Address 1600 AMPHITHEATRE PKWY MOUNTAIN VIEW CA 94043
Business Address 1600 AMPHITHEATRE PKWY MOUNTAIN VIEW CA 94043 650-335-5278
GV 2019, L.P. (Filed by) CIK: 0001845041 (see all company filings)

EIN.: 384092634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Subject) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-93800 | Film No.: 251473423
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)